Abiomed’s HDE application
This article was originally published in The Gray Sheet
Executive Summary
AbioCor humanitarian device exemption is "on track and proceeding as expected," despite the early wear-out of a bearing that resulted in the death of a patient implanted with the artificial heart, CEO Michael Minogue says Oct. 21. According to the firm's investigation, the premature bearing wear-out was due to a combination of the patient's cardiovascular anatomy and the limited range of a shutter to control blood flow, which placed excessive loads on the system. The firm has taken immediate actions to prevent recurrence, including changing the manufacturing selection process of the shutter and guidelines for device and patient management, Abiomed reports. Under the Sept. 1 HDE, the firm is seeking an AbioCor indication to treat a defined subset of irreversible end-stage heart failure patients (1"The Gray Sheet" Sept. 13, 2004, In Brief)...
You may also be interested in...
Abiomed seeks HDE approval
Danvers, Mass. firm submits humanitarian device exemption application for its AbioCor implantable replacement heart Sept. 1 and anticipates HDE approval by the end of its fiscal year in March 2005 (1"The Gray Sheet" April 19, 2004, p. 23). Abiomed has enrolled 14 of 15 patients for its clinical trial, the firm also notes Sept. 8...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.